Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.
Cejalvo MJ, Bustamante G, González E, Vázquez-Álvarez J, García R, Ramírez-Payer Á, Pérez-Persona E, Abella E, Garzón S, García A, Jarque I, González MS, Sampol A, Motlló C, Martí JM, Alcalá M, Duro R, González Y, Sastre JL, Sarrà J, Lostaunau G, López R, de la Rubia J. Cejalvo MJ, et al. Among authors: garzon s. Ann Hematol. 2021 Jul;100(7):1769-1778. doi: 10.1007/s00277-021-04529-5. Epub 2021 Apr 22. Ann Hematol. 2021. PMID: 33885924
Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation.
de Arriba de la Fuente F, Durán MS, Álvarez MÁ, Sanromán IL, Dios AM, Ríos Tamayo R, García R, González MS, Prieto E, Bárez A, Escalante F, Tejedor A, Ballesteros M, Cabañas V, Capote FJ, Couto C, Garzón S, González-Pardo M, Mateos Manteca MV. de Arriba de la Fuente F, et al. Among authors: garzon s. Semin Hematol. 2018 Oct;55(4):189-196. doi: 10.1053/j.seminhematol.2017.09.002. Epub 2017 Oct 13. Semin Hematol. 2018. PMID: 30502846 Review.
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.
Puig N, Hernández MT, Rosiñol L, González E, de Arriba F, Oriol A, González-Calle V, Escalante F, de la Rubia J, Gironella M, Ríos R, García-Sánchez R, Arguiñano JM, Alegre A, Martín J, Gutiérrez NC, Calasanz MJ, Martín ML, Couto MDC, Casanova M, Arnao M, Pérez-Persona E, Garzón S, González MS, Martín-Sánchez G, Ocio EM, Coleman M, Encinas C, Vale AM, Teruel AI, Cortés-Rodríguez M, Paiva B, Cedena MT, San-Miguel JF, Lahuerta JJ, Bladé J, Niesvizky R, Mateos MV. Puig N, et al. Among authors: garzon s. Blood Cancer J. 2021 May 21;11(5):101. doi: 10.1038/s41408-021-00490-8. Blood Cancer J. 2021. PMID: 34021118 Free PMC article. Clinical Trial.
Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study.
Ocio EM, Montes-Gaisán C, Bustamante G, Garzón S, González E, Pérez E, Sirvent M, Arguiñano JM, González Y, Ríos R, de Miguel D, Grande M, Fernández A, Naves A, Rosiñol L. Ocio EM, et al. Among authors: garzon s. Clin Lymphoma Myeloma Leuk. 2022 Apr;22(4):e241-e249. doi: 10.1016/j.clml.2021.10.001. Epub 2021 Oct 8. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34774462 Free article.
Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study.
Ocio EM, Montes-Gaisán C, Bustamante G, Garzón S, González E, Pérez-Persona E, González-Calle V, Sirvent M, Arguiñano JM, González Y, Ríos R, de Miguel D, Grande M, Fernández-Nistal A, Naves A, Rosiñol L. Ocio EM, et al. Among authors: garzon s. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):e341-e347. doi: 10.1016/j.clml.2023.07.006. Epub 2023 Jul 15. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37517875 Free article.
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, Lahuerta JJ, Fernández-Rañada JM, Hernández MT, Alonso N, García Vela JA, Garzón S, Rodríguez J, Caballero D; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO). Arranz R, et al. Among authors: garzon s. Eur J Haematol. 2008 Mar;80(3):227-35. doi: 10.1111/j.1600-0609.2007.01020.x. Epub 2007 Dec 18. Eur J Haematol. 2008. PMID: 18088400 Clinical Trial.
Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study.
Jurado M, De La Mata C, Ruiz-García A, López-Fernández E, Espinosa O, Remigia MJ, Moratalla L, Goterris R, García-Martín P, Ruiz-Cabello F, Garzón S, Pascual MJ, Espigado I, Solano C. Jurado M, et al. Among authors: garzon s. Cytotherapy. 2017 Aug;19(8):927-936. doi: 10.1016/j.jcyt.2017.05.002. Epub 2017 Jun 26. Cytotherapy. 2017. PMID: 28662983 Clinical Trial.
Differential epigenetic regulation between the alternative promoters, PRDM1α and PRDM1β, of the tumour suppressor gene PRDM1 in human multiple myeloma cells.
Romero-García R, Gómez-Jaramillo L, Mateos RM, Jiménez-Gómez G, Pedreño-Horrillo N, Foncubierta E, Rodríguez-Gutiérrez JF, Garzón S, Mora-López F, Rodríguez C, Valor LM, Campos-Caro A. Romero-García R, et al. Among authors: garzon s. Sci Rep. 2020 Sep 28;10(1):15899. doi: 10.1038/s41598-020-72946-z. Sci Rep. 2020. PMID: 32985591 Free PMC article.
285 results